Julie Eskay-Eagle

Lazard Frères Real Estate Investors LLC is a Private Equity firm, a subsidiary of Lazard Frères & Co. LLC founded in the year 1994. The firm is headquartered in New York.

Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent.

Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Lazard Technology Partners LLC (Lazard Technology Partners) is a venture capital subsidiary of LAI Partners LLC founded in 1998 by Russell Planitzer and Kevin Burns. The firm is headquartered in New York.

Vitae Pharmaceuticals LLC is a clinical-stage bio-pharmaceutical company, which engages in discovering and developing novel, small molecule drugs for diseases, including chronic kidney disease, diabetes and Alzheimer's disease, and autoimmune disorders, acute coronary syndrome, and immuno-oncology. The company was founded by John J. Baldwin, Bartosz A. Grzybowski, George M. Whitesides, and Eugene Shakhnovich on May 21, 2001 and is headquartered in Fort Washington, PA.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

ProteinSimple engages in the proprietary systems and consumables for protein analysis. Its products include simple plex, ice, simple western, micro-flow imaging, and single-cell western. The company was founded by Linda Cahill, Nancy Allbritton, Christopher Sims, Scott Lockard, and Jim Schlater in December 2000 and is headquartered in San Jose, CA.

Health Evolution Management Co. LLC (Health Evolution Management) is a private equity firm founded in 2007 by David J. Brailer. The firm is headquartered in San Francisco, California.